Stockscreener 앱 받기
5.12
2.48%
-0.13
시장 영업 전:
5.12
전일 마감가:
$5.25
열려 있는:
$5.3
하루 거래량:
440.19K
Relative Volume:
1.11
시가총액:
$108.51M
수익:
$73.62M
순이익/손실:
$-138.24M
주가수익비율:
-0.7805
EPS:
-6.56
순현금흐름:
$-99.19M
1주 성능:
+5.79%
1개월 성능:
-18.47%
6개월 성능:
-64.25%
1년 성능:
-56.28%
1일 변동 폭
$5.02
$5.3298
1주일 범위
$4.71
$5.3298
52주 변동 폭
$4.71
$17.80
Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile
명칭
Enanta Pharmaceuticals Inc
전화
617 607 0800
주소
500 ARSENAL STREET, WATERTOWN, MA
ENTA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ENTA
Enanta Pharmaceuticals Inc
|
5.12 | 108.51M | 73.62M | -138.24M | -99.19M | -6.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-08-09 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-08-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-12-09 | 개시 | H.C. Wainwright | Buy |
| 2022-07-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2022-06-01 | 업그레이드 | Evercore ISI | Underperform → In-line |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-09-09 | 개시 | SVB Leerink | Mkt Perform |
| 2021-01-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2020-11-24 | 개시 | Evercore ISI | Underperform |
| 2020-08-28 | 재개 | ROTH Capital | Buy |
| 2020-08-26 | 개시 | Piper Sandler | Overweight |
| 2020-07-27 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2020-03-17 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2019-11-22 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-26 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-05-24 | 개시 | Wolfe Research | Outperform |
| 2019-04-23 | 업그레이드 | Berenberg | Hold → Buy |
| 2018-12-13 | 개시 | Berenberg | Hold |
| 2018-06-06 | 개시 | ROTH Capital | Buy |
| 2018-02-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-01-02 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-11-21 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-07-11 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2016-04-28 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | 재확인 | Barclays | Underweight |
| 2015-10-23 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2015-10-23 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
모두보기
Enanta Pharmaceuticals Inc 주식(ENTA)의 최신 뉴스
JPMorgan Chase & Co. Increases Stock Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Purchased by JPMorgan Chase & Co. - MarketBeat
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Bought by Barclays PLC - Defense World
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives $17.25 Average Target Price from Brokerages - MarketBeat
Enanta stock hits 52-week low at $4.83 amid market challenges - Investing.com Nigeria
Enanta stock hits 52-week low at $4.83 amid market challenges By Investing.com - Investing.com South Africa
Jane Street Group LLC Has $240,000 Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World
ENTA (Enanta Pharmaceuticals) Peter Lynch Fair Value : N/A (As of Jan. 11, 2025) - GuruFocus.com
Enanta stock hits 52-week low at $5.29 amid market challenges - Investing.com Nigeria
Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Purchased by Barclays PLC - Defense World
Geode Capital Management LLC Has $4.95 Million Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World
(ENTA) Technical Pivots with Risk Controls - Stock Traders Daily
Enanta stock touches 52-week low at $5.68 amid market challenges - Investing.com Australia
Enanta stock touches 52-week low at $5.68 amid market challenges By Investing.com - Investing.com South Africa
Brokers Issue Forecasts for ENTA Q1 Earnings - Defense World
Equities Analysts Offer Predictions for ENTA Q1 Earnings - MarketBeat
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
FY2029 Earnings Estimate for ENTA Issued By HC Wainwright - Defense World
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives $17.25 Average PT from Brokerages - MarketBeat
Enanta Pharmaceuticals (NASDAQ:ENTA) Price Target Cut to $18.00 by Analysts at HC Wainwright - Defense World
Equities Analysts Set Expectations for ENTA FY2029 Earnings - MarketBeat
Pfizer prevails in Enanta patent case over Covid-19 drug By Investing.com - Investing.com Nigeria
Enanta Pharmaceuticals stock remains Buy-rated with Phase 2 data driving model revisions - Investing.com Australia
When (ENTA) Moves Investors should Listen - Stock Traders Daily
Pfizer prevails in Enanta patent case over Covid-19 drug - Investing.com India
Pfizer Gets Enanta Patent Voided in Case Over Paxlovid Royalties - Bloomberg Law
Enanta Pharmaceuticals (ENTA) Appeals Court Ruling in Patent Dis - GuruFocus.com
HC Wainwright Cuts Enanta Pharmaceuticals (NASDAQ:ENTA) Price Target to $18.00 - MarketBeat
Enanta to appeal as Pfizer wins Paxlovid patent ruling - MSN
Enanta stock slips as Pfizer wins Paxlovid patent (PFE:NYSE) - Seeking Alpha
Enanta Pharmaceuticals to Appeal Ruling in Patent Infringement Case Against Pfizer - MarketWatch
Enanta Pharma Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) - Benzinga
Enanta Loses Key Patent Battle Against Pfizer Over COVID Drug Paxlovid in Court Ruling - StockTitan
Enanta Pharmaceuticals (ENTA) Moves 7.2% Higher: Will This Strength Last? - Yahoo Finance
Fmr LLC Purchases 7,839 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 27,597 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World
Charles Schwab Investment Management Inc. Sells 1,649 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World
Enanta Pharmaceuticals' SWOT analysis: RSV pipeline progress buoys stock outlook - Investing.com
(ENTA) Technical Data - Stock Traders Daily
Enanta stock touches 52-week low at $6.36 amid market challenges - Investing.com Canada
FY2025 Earnings Estimate for ENTA Issued By Leerink Partnrs - Defense World
Enanta Pharmaceuticals Inc (ENTA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):